ライフサイエンスコーパス: fatty liver

1 patic lipid metabolism and its loss leads to fatty liver.

2 h impaired lipolytic regulation resulting in fatty liver.

3 be protective against insulin resistance and fatty liver.

4 nd liver-specific deletion of HDAC3 leads to fatty liver.

5 lcohol administration, and not a function of fatty liver.

6 c background, diet, and physical activity on fatty liver.

7 iseases involving diffusive patterns such as fatty liver.

8 onsequence of chronic EtOH insult leading to fatty liver.

9 adipose tissue, marked IR, dyslipidemia, and fatty liver.

10 e (RetSat) is involved in the development of fatty liver.

11 through disruption of Jak2 (JAK2L) leads to fatty liver.

12 The hepatic transcriptome of such mice with fatty liver (8 weeks), steatohepatitis with early fibros

13 were used to predict diabetes, hypertension, fatty liver, a combination of these three chronic diseas

14 Fatty liver accumulation results from an imbalance betwe

15 erase normalization, age, and a nonalcoholic fatty liver activity score >/=5 may be useful to identif

16 elivery prevents HFD-induced weight gain and fatty liver, alleviates obesity-induced chronic inflamma

17 nosed on established ultrasound criteria for fatty liver and absent alcohol consumption.

18 n of lnc-KDM5D-4 in key processes related to fatty liver and cellular inflammation associated with at

19 contribute to metabolic disorders, including fatty liver and diabetes.

20 erapeutic target to treat obesity-associated fatty liver and insulin resistance.Hepatic steatosis is

21 heir potential effects on the development of fatty liver and nonalcoholic steatohepatitis.

22 lithiasis, one (2%) biliary sludge, one (2%) fatty liver and none hepatomegaly.

23 ng contributes to steatosis and nonalcoholic fatty liver and obesity.

24 ulin sensitivity and responsiveness, despite fatty liver and obesity.

25 how that PKC activity, which correlates with fatty liver and which causes insulin resistance, was sig

26 ice also had elevated fasting blood glucose, fatty liver, and insulin resistance.

27 med lnc-KDM5D-4, and investigate its role in fatty liver-associated atherosclerosis.

28 viously, we demonstrated that development of fatty liver depends on adipocyte GH signaling.

29 liver-specific Shp deletion protects against fatty liver development by suppressing expression of per

30 Fatty liver development was associated with transcriptio

31 rofile were observed already 10 years before fatty liver diagnosis.

32 Non-alcoholic and alcoholic fatty liver disease (NAFLD and AFLD, respectively) are m

33 = 3-5) and in human samples of non-alcoholic fatty liver disease (NAFLD) (n = 72-135).

34 Nonalcoholic fatty liver disease (NAFLD) alters drug response.

35 sease activity in patients with nonalcoholic fatty liver disease (NAFLD) and alcoholic liver disease

36 Nonalcoholic fatty liver disease (NAFLD) and alcoholic liver disease

37 ity-related diseases, including nonalcoholic fatty liver disease (NAFLD) and diabetes, and has receiv

38 fat is a likely contributor to nonalcoholic fatty liver disease (NAFLD) and insulin resistance, but

39 bling the phenotype observed in nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepat

40 Nonalcoholic fatty liver disease (NAFLD) and resulting nonalcoholic s

41 The early stages of nonalcoholic fatty liver disease (NAFLD) are characterized by the acc

42 e obesity, type 2 diabetes, and nonalcoholic fatty liver disease (NAFLD) are replacing viral- and alc

43 tent inclusion of subjects with nonalcoholic fatty liver disease (NAFLD) as controls can compromise s

44 A may impair renal function in non alcoholic fatty liver disease (NAFLD) by altering inflammatory sig

45 ceride (IHTG) content to define nonalcoholic fatty liver disease (NAFLD) by proton magnetic resonance

46 Nonalcoholic fatty liver disease (NAFLD) can progress from simple ste

47 Nonalcoholic fatty liver disease (NAFLD) comprises a spectrum of hist

48 Nonalcoholic fatty liver disease (NAFLD) contributes to premature dea

49 effective hepatitis C therapy, non-alcoholic fatty liver disease (NAFLD) could soon emerge as the mos

50 Nonalcoholic fatty liver disease (NAFLD) encompasses a spectrum of li

51 ue, are accurate for diagnosing nonalcoholic fatty liver disease (NAFLD) fibrosis.

52 Nonalcoholic fatty liver disease (NAFLD) has become a major public he

53 Nonalcoholic fatty liver disease (NAFLD) has become highly prevalent,

54 Non-alcoholic fatty liver disease (NAFLD) has been recently identified

55 ation between periodontitis and nonalcoholic fatty liver disease (NAFLD) has been reported by experim

56 Pediatric nonalcoholic fatty liver disease (NAFLD) histology demonstrates varia

57 ion in bariatric patients with non-alcoholic fatty liver disease (NAFLD) in a randomized clinical tri

58 Nonalcoholic fatty liver disease (NAFLD) in non-obese patients remain

59 pendent biomarker of CT-defined nonalcoholic fatty liver disease (NAFLD) in the offspring cohort of t

60 The histologic spectrum of nonalcoholic fatty liver disease (NAFLD) includes fatty liver (NAFL)

61 The incidence of non-alcoholic fatty liver disease (NAFLD) increases with age.

62 Nonalcoholic fatty liver disease (NAFLD) is a burgeoning health probl

63 Non-alcoholic fatty liver disease (NAFLD) is a common metabolic disord

64 Nonalcoholic fatty liver disease (NAFLD) is a common problem across t

65 Nonalcoholic fatty liver disease (NAFLD) is a complex chronic liver d

66 BACKGROUND & AIMS: Nonalcoholic fatty liver disease (NAFLD) is a consequence of defects

67 Nonalcoholic fatty liver disease (NAFLD) is a leading cause of liver

68 Nonalcoholic fatty liver disease (NAFLD) is a major cause of chronic

69 Non-alcoholic fatty liver disease (NAFLD) is a major risk factor leadi

70 Nonalcoholic fatty liver disease (NAFLD) is a risk factor for type 2

71 Nonalcoholic fatty liver disease (NAFLD) is a significant health burd

72 There is evidence that nonalcoholic fatty liver disease (NAFLD) is affected by gut microbiot

73 er fibrosis among patients with nonalcoholic fatty liver disease (NAFLD) is an important clinical nee

74 Nonalcoholic fatty liver disease (NAFLD) is an increasing health prob

75 BACKGROUND & AIMS: Nonalcoholic fatty liver disease (NAFLD) is associated with increased

76 Nonalcoholic fatty liver disease (NAFLD) is associated with increased

77 Nonalcoholic fatty liver disease (NAFLD) is characterized by excess a

78 Nonalcoholic fatty liver disease (NAFLD) is characterized by the accu

79 Although nonalcoholic fatty liver disease (NAFLD) is closely linked to obesity

80 ol consumption in patients with nonalcoholic fatty liver disease (NAFLD) is common, yet the effects o

81 Nonalcoholic fatty liver disease (NAFLD) is highly prevalent and asso

82 of FOXOs in the development of nonalcoholic fatty liver disease (NAFLD) is not well understood.

83 Nonalcoholic fatty liver disease (NAFLD) is now the most common form

84 Non-alcoholic fatty liver disease (NAFLD) is one of the most frequent

85 Nonalcoholic fatty liver disease (NAFLD) is the most common cause of

86 Nonalcoholic fatty liver disease (NAFLD) is the most common cause of

87 Nonalcoholic fatty liver disease (NAFLD) is the most common chronic l

88 Nonalcoholic fatty liver disease (NAFLD) is the most common chronic l

89 Non-alcoholic fatty liver disease (NAFLD) is the most common liver dis

90 Nonalcoholic fatty liver disease (NAFLD) is the most prevalent liver

91 Nonalcoholic fatty liver disease (NAFLD) is widespread in adults and

92 development and progression of nonalcoholic fatty liver disease (NAFLD) over time is lacking.

93 mong HIV-infected patients with nonalcoholic fatty liver disease (NAFLD) receiving EFV plus 2 nucleos

94 Non-alcoholic fatty liver disease (NAFLD) represents a spectrum of con

95 Nonalcoholic fatty liver disease (NAFLD) represents an emerging cause

96 Nonalcoholic fatty liver disease (NAFLD) represents the hepatic manif

97 AR in disease progression from non-alcoholic fatty liver disease (NAFLD) to HCC.

98 Nonalcoholic fatty liver disease (NAFLD) was the most common cause of

99 Nonalcoholic fatty liver disease (NAFLD), a common prelude to cirrhos

100 sensitivity are widely used in nonalcoholic fatty liver disease (NAFLD), although they have never be

101 is frequently associated with non-alcoholic fatty liver disease (NAFLD), but the mechanisms involved

102 linically aggressive variant of nonalcoholic fatty liver disease (NAFLD), is becoming an increasingly

103 In non-alcoholic fatty liver disease (NAFLD), lipid build-up and the resu

104 sting-is often misdiagnosed as non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatit

105 tivation may induce obesity and nonalcoholic fatty liver disease (NAFLD), one of the most challenging

106 Nonalcoholic fatty liver disease (NAFLD), the most common form of chr

107 Despite the high prevalence of nonalcoholic fatty liver disease (NAFLD), therapeutic options and non

108 tes has been recently linked to nonalcoholic fatty liver disease (NAFLD), which is known to associate

109 idative damage are features of non-alcoholic fatty liver disease (NAFLD).

110 rtant predictor of mortality in nonalcoholic fatty liver disease (NAFLD).

111 ram liver for increased risk of nonalcoholic fatty liver disease (NAFLD).

112 lt patients suspected of having nonalcoholic fatty liver disease (NAFLD).

113 betes (T2D), and improvement of nonalcoholic fatty liver disease (NAFLD).

114 -F), a potential biomarker for non-alcoholic fatty liver disease (NAFLD).

115 um, is strongly associated with nonalcoholic fatty liver disease (NAFLD).

116 e severity of liver fibrosis in nonalcoholic fatty liver disease (NAFLD).

117 d GCKR p.P446L) associated with nonalcoholic fatty liver disease (NAFLD).

118 MOylation to the development of nonalcoholic fatty liver disease (NAFLD).

119 and steatosis in patients with nonalcoholic fatty liver disease (NAFLD).

120 and steatosis in patients with nonalcoholic fatty liver disease (NAFLD).

121 r in drug induced (DIS) and/or non-alcoholic fatty liver disease (NAFLD).

122 d the role of gut microbiota in nonalcoholic fatty liver disease (NAFLD).

123 s in different murine models of nonalcoholic fatty liver disease (NAFLD).

124 obesity, a key risk factor for nonalcoholic fatty liver disease (NAFLD).

125 ull spectrum of liver damage in nonalcoholic fatty liver disease (NAFLD).

126 major determinant of outcome in nonalcoholic fatty liver disease (NAFLD).

127 usal role in the progression of nonalcoholic fatty liver disease (NAFLD).

128 in pre-diabetic patients with non-alcoholic fatty liver disease (NAFLD).

129 se of death among patients with nonalcoholic fatty liver disease (NAFLD).

130 espite this, little evidence of nonalcoholic fatty liver disease (NAFLD)/nonalcoholic steatohepatitis

131 ), are often found increased in nonalcoholic fatty liver disease (NAFLD); however, if this is due to

132 other sugars has been linked to nonalcoholic fatty liver disease (NAFLD); however, the sugar-associat

133 Nonalcoholic fatty liver disease (steatosis) is the most prevalent li

134 0.49, P = 2.35 x 10(-6) ), and nonalcoholic fatty liver disease activity score (r = 0.48, P = 4.69 x

135 ression, adjusting for baseline nonalcoholic fatty liver disease activity score.

136 ith (1) histologic diagnosis of nonalcoholic fatty liver disease and (2) self-reported information on

137 ed lipid metabolism, thereby contributing to fatty liver disease and atherosclerosis.

138 t-related health issues such as nonalcoholic fatty liver disease and cardiovascular disorders are kno

139 gree relatives of patients with nonalcoholic fatty liver disease and cirrhosis (NAFLD-cirrhosis) is u

140 ith liver disease, particularly nonalcoholic fatty liver disease and cirrhosis, and this was true eve

141 iseases, including type 2 diabetes, obesity, fatty liver disease and diabetic cardiomyopathy.

142 that liver targeted deletion of Mecp2 causes fatty liver disease and dyslipidemia similar to HDAC3 li

143 Non-alcoholic fatty liver disease and early fibrosis were induced by t

144 near-complete protection from development of fatty liver disease and glucose dysmetabolism.

145 e KO mice developed features of nonalcoholic fatty liver disease and had increased levels of reactive

146 fection is partly responsible for hepatitis, fatty liver disease and hepatocellular carcinoma (HCC).

147 ial overlap with biomarkers of non-alcoholic fatty liver disease and its progression to steatohepatos

148 2* and to identify clinical associations for fatty liver disease and liver iron overload and their pr

149 ic capacity increases risk for non-alcoholic fatty liver disease and liver-related disease mortality,

150 tein metabolism, alcoholic and non-alcoholic fatty liver disease and myocardial infarction in multipl

151 gy-dense diets has led to an endemic rise in fatty liver disease and obesity.

152 26 is a genetic risk factor for nonalcoholic fatty liver disease and progression to fibrosis but is p

153 metabolic diseases, including non-alcoholic fatty liver disease and type 2 diabetes.

154 our eligible patients who have non-alcoholic fatty liver disease and who are insulin resistant, will

155 People with fatty liver disease are at high risk of magnesium defici

156 coholic liver disease (ALD) and nonalcoholic fatty liver disease are characterized by massive lipid a

157 such as insulin resistance and non-alcoholic fatty liver disease are reaching epidemic proportions.

158 given the aging population and nonalcoholic fatty liver disease as a leading indication for transpla

159 ne is associated with pediatric nonalcoholic fatty liver disease but may confer protection against ca

160 s observed in a subset of human nonalcoholic fatty liver disease cases.

161 Thus, severe fatty liver disease develops early in lipodystrophic mic

162 PRI), fibrosis-4 (FIB-4) score, nonalcoholic fatty liver disease fibrosis score (NFS), and Forns scor

163 a large (XL+), in patients with nonalcoholic fatty liver disease in a multicenter setting.

164 normal metabolism and elevated the risk for fatty liver disease in mice maintained on a high-fat die

165 vents metabolic stress-induced non-alcoholic fatty liver disease in mice.

166 with sugar, mimicking a Western diet, causes fatty liver disease in mice.

167 ane 6 superfamily member 2 (TM6SF2) gene and fatty liver disease in obese youth.

168 brosis in humans and mice with non-alcoholic fatty liver disease is accompanied by accumulation of li

169 Nonalcoholic fatty liver disease is associated with hepatic insulin r

170 Non-alcoholic fatty liver disease is associated with hepatocellular ca

171 Nonalcoholic fatty liver disease is associated with metabolic risk fa

172 Nonalcoholic fatty liver disease is becoming the most common chronic

173 Fatty liver disease is common in the United States and w

174 Nonalcoholic fatty liver disease is increasing in prevalence.

175 Nonalcoholic fatty liver disease is one of the most prevalent metabol

176 The cause of nonalcoholic fatty liver disease is the aberrant accumulation of lipi

177 Non-alcoholic fatty liver disease is the most rapidly growing form of

178 The progressive non-alcoholic fatty liver disease observed in the LCR rats following w

179 in percentages of patients with nonalcoholic fatty liver disease or ALD.

180 patients, 30 NASH patients, 31 nonalcoholic fatty liver disease patients (without histology), and 43

181 ed with severity of fibrosis in nonalcoholic fatty liver disease patients of European ancestry, likel

182 sion in a diet-induced model of nonalcoholic fatty liver disease reveals onset of hepatic copper defi

183 Here we explore the progression of fatty liver disease using a mouse model of lipodystrophy

184 Incident nonalcoholic fatty liver disease was highest in patients with PsO pre

185 gained more weight and developed exacerbated fatty liver disease when fed a HFD compared with WT mice

186 besity is the direct cause (eg, nonalcoholic fatty liver disease) or is a significant risk factor, su

187 nd has been implicated in the development of fatty liver disease, although its role in biliary hyperp

188 sity, type 2 diabetes mellitus, nonalcoholic fatty liver disease, and cardiovascular disease.

189 nterest were any liver disease, nonalcoholic fatty liver disease, and cirrhosis (any etiology).

190 , and metabolic (i.e. obesity, non-alcoholic fatty liver disease, and diabetes) and neurological dise

191 age in alcoholic liver disease, nonalcoholic fatty liver disease, and hepatitis C, but no data are av

192 on of alcoholic liver disease, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis i

193 sistance and diabetes mellitus, nonalcoholic fatty liver disease, and obesity.

194 ves cardiovascular disease, type 2 diabetes, fatty liver disease, and several cancers.

195 lack innate suckling activities, and develop fatty liver disease, arrested alveologenesis in the lung

196 otein 3 (PNPLA3) is strongly associated with fatty liver disease, but the underlying mechanism remain

197 and obesity are associated with nonalcoholic fatty liver disease, cardiomyopathy, and cardiovascular

198 o be more lipogenic, promoting dyslipidemia, fatty liver disease, cardiovascular disease, and diabete

199 cancer, liver disease including nonalcoholic fatty liver disease, cirrhosis, hepatocellular carcinoma

200 mellitus, psoriatic arthritis, nonalcoholic fatty liver disease, depression, anxiety, and decreased

201 In nonalcoholic fatty liver disease, Gal-9 is involved indirectly in the

202 tors of liver disease, such as non-alcoholic fatty liver disease, hazardous alcohol use, or type 2 di

203 insulin-resistant patients with nonalcoholic fatty liver disease, hepatic mIndy expression was increa

204 d metabolism, particularly in the context of fatty liver disease, is unclear.

205 ion of liver diseases, such as non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, prim

206 were evaluated in patients with nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, or en

207 ns of those with HCV infection, nonalcoholic fatty liver disease, or ALD did not change between 2003

208 fibrosis (viral hepatitis C vs nonalcoholic fatty liver disease, P = .025), inflammation (severe vs

209 rapeutic approach for Type-2 diabetes and/or fatty liver disease, so far, only a few SLC13A5 inhibito

210 es mellitus has been linked to non-alcoholic fatty liver disease, which can progress to inflammation,

211 ablation of Tnfaip3 exacerbated nonalcoholic fatty liver disease- and NASH-related phenotypes in mice

212 breast cancer, and in degree and duration of fatty liver disease-related hepatocellular carcinoma.

213 osis in pediatric patients with nonalcoholic fatty liver disease.

214 eing overtaken by patients with nonalcoholic fatty liver disease.

215 nditions including obesity and non-alcoholic fatty liver disease.

216 erosis, increased obesity, and non-alcoholic fatty liver disease.

217 ver that hepatic SHP is necessary to promote fatty liver disease.

218 a novel therapeutic target for non-alcoholic fatty liver disease.

219 failure rates in patients with nonalcoholic fatty liver disease.

220 a docking protein-governs the development of fatty liver disease.

221 pplications in diseases such as nonalcoholic fatty liver disease.

222 ion confers protection against non-alcoholic fatty liver disease.

223 in livers of obese mice and in patients with fatty liver disease.

224 ed in fatty liver formation in non-alcoholic fatty liver disease.

225 d gamma-glutamyl transferase, two markers of fatty liver disease.

226 e novo lipogenesis involved in non-alcoholic fatty liver disease.

227 e a potential role for Vpr in HIV-associated fatty liver disease.

228 among postmenopausal women with nonalcoholic fatty liver disease.

229 e targets for the treatment of non-alcoholic fatty liver disease.

230 c role of PHLPP2 activators in non-alcoholic fatty liver disease.

231 , and insulin resistance in murine models of fatty liver disease.

232 otential therapeutic target for nonalcoholic fatty liver disease.

233 of alcoholic liver disease and nonalcoholic fatty liver disease.

234 to oxidative stress and declines in advanced fatty liver disease.

235 in the liver of ob/ob mice and patients with fatty liver disease.

236 of alcoholic liver disease and nonalcoholic fatty liver disease.

237 asting results were reported in nonalcoholic fatty liver disease.

238 fferent aspects of both ALD and nonalcoholic fatty liver disease.

239 tified 15 lncRNAs, which are associated with fatty liver disease.

240 r fibrosis or cirrhosis and 20 controls with fatty liver disease.

241 SREBP target genes and developed spontaneous fatty liver disease.

242 about the metabolic perturbations preceding fatty liver disease.

243 otential in obese patients with nonalcoholic fatty liver disease.

244 an increase in the incidence of nonalcoholic fatty liver disease.

245 ther hepatic diseases, such as non-alcoholic fatty liver disease.

246 metabolic syndrome, including non-alcoholic fatty liver disease.

247 ntribute to the development of non-alcoholic fatty liver disease.

248 e in the protection against the diet-induced fatty liver disease.

249 es such as type 2 diabetes and non-alcoholic fatty liver disease.

250 ) with histologically confirmed nonalcoholic fatty liver disease.

251 nd emergence of cirrhosis from non-alcoholic fatty liver disease.

252 flammation, and fibrosis in animal models of fatty liver disease.

253 be a therapeutic target for the treatment of fatty liver disease.

254 d diabetes can be attributed to nonalcoholic fatty liver disease.

255 hypertrophy, and present with non-alcoholic fatty liver disease; 3) DKO mice demonstrate HF diet-ind

256 ronic hepatitis C; hepatitis B; nonalcoholic fatty liver diseases (NAFLD); and alcoholic liver diseas

257 Prevalence of fatty liver diseases and iron overload was calculated (w

258 a white German population, the prevalence of fatty liver diseases and liver iron overload is 42.2% (1

259 Prevalence of fatty liver diseases was 42.2% (1082 of 2561 participant

260 G in the liver of patients with nonalcoholic fatty liver diseases.

261 reported liver disease, including hepatitis, fatty liver, enlarged liver and cirrhosis, was validated

262 let coat protein that has been implicated in fatty liver formation in non-alcoholic fatty liver disea

263 can further be used to differentiate between fatty liver from healthy liver in an experimentally arri

264 F and its pro-form, pro-NGF, are elevated in fatty livers from leptin-deficient mice compared with co

265 ese insulin-resistant humans with or without fatty liver, giving rise to oxidative stress and decline

266 In liver steatosis (i.e. fatty liver), hepatocytes accumulate many large neutral

267 ation and inflammation in metabolic tissues, fatty livers, hyperglycaemia and insulin resistance reca

268 Sucrose feeding, which is required to elicit fatty liver in KI mice, led to a much larger and more pe

269 s obesity, diabetes, insulin resistance, and fatty liver in mice.

270 rations appear to precede the development of fatty liver in young adults.

271 reflect the presence of and future risk for fatty liver in young adults.

272 receptor (Ldlr(-/-)T39(-/-)) show decreased fatty liver, increased high-density lipoprotein, decreas

273 lipids, fatty acids, and amino acids reflect fatty liver independently of routine metabolic risk fact

274 chotomized CAP, US, body mass indexes (BMI), fatty liver index (FLI) and hepatic steatosis index (HSI

275 ), and liver steatosis by sonography and the fatty liver index (FLI).

276 54 +/- 138 versus 49 +/- 35 IU/L (P = 0.72), Fatty Liver Index 58.9 +/- 24.6 versus 61.2 +/- 22.9 (P

277 Fatty liver induces a c-Jun-mediated decrease in ITPR2 i

278 Nonalcoholic fatty liver is associated with obesity-related metabolic

279 present a therapeutic approach for steatosis.Fatty liver is one of the major features of metabolic sy

280 Protection against fatty liver is partially recapitulated by the systemic a

281 ing chronic hepatosteatosis resembling human fatty liver, lowers hepatic nicotinamide adenine dinucle

282 In high-fat diet induced fatty-liver mice, AM580 reduced ApoC-III levels in liver

283 Findings showed only Testos group exhibited fatty liver morphology and higher levels of ketogenic an

284 coholic fatty liver disease (NAFLD) includes fatty liver (NAFL) and steatohepatitis (NASH), which can

285 NASH is a potential outcome of nonalcoholic fatty liver (NAFL), a condition that occurs when lipids

286 ecutive patients diagnosed with nonalcoholic fatty liver (NAFL), nonalcoholic steatohepatitis (NASH),

287 ss from simple steatosis (i.e., nonalcoholic fatty liver [NAFL]) to nonalcoholic steatohepatitis (NAS

288 as well as liver-specific disorders such as fatty liver, nonalcoholic steatohepatitis, and hepatocel

289 sis stage (F0-F4) and as having nonalcoholic fatty liver or nonalcoholic steatohepatitis (NASH).

290 Fatty liver outcomes were compared with lean liver to as

291 Fatty liver, oxidative stress, and mitochondrial dysfunc

292 ere strongly associated with the presence of fatty liver (P < 0.0007 for 60 measures in age-adjusted

293 l activity of CUGBP1 causes development of a fatty liver phenotype in young S302A mice.

294 tage (e.g., higher in NASH than nonalcoholic fatty liver, positive correlation with fibrosis score an

295 pathway was altered in a model of alcoholic fatty liver, primary hepatocytes from rats fed a 6-week

296 the fact that its synthetic agonists induce fatty liver, the liver X receptor (LXR) transcription fa

297 Fatty liver was associated with a deregulated liver expr

298 Fatty liver was diagnosed by ultrasound in 2011 when par

299 Fatty liver was diagnosed using liver ultrasound.

300 ions as well as 4-year and 10-year risks for fatty liver were assessed by logistic regression.